Lund JL - Search Results

1

Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.

Cole AL, Wood WA Jr, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB. Cole AL, et al. Among authors: lund jl. JCO Oncol Pract. 2020 May;16(5):e443-e455. doi: 10.1200/JOP.19.00301. Epub 2020 Mar 20. JCO Oncol Pract. 2020. PMID: 32196424

2

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sanoff HK, et al. Among authors: lund jl. Oncologist. 2016 Sep;21(9):1113-20. doi: 10.1634/theoncologist.2015-0478. Epub 2016 May 16. Oncologist. 2016. PMID: 27185615 Free PMC article.

3

Immortal time bias or sorafenib effect in elderly patients with HCC?

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sanoff HK, et al. Among authors: lund jl. Hepatology. 2017 Aug;66(2):678-679. doi: 10.1002/hep.29250. Epub 2017 Jun 28. Hepatology. 2017. PMID: 28510340 Free article. No abstract available.

4

Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, Lund JL. Hester LL, et al. Among authors: lund jl. Cancer. 2019 Apr 1;125(7):1101-1112. doi: 10.1002/cncr.31821. Epub 2018 Dec 11. Cancer. 2019. PMID: 30548238 Free PMC article.

5

Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.

Mitchell AP, Winn AN, Lund JL, Dusetzina SB. Mitchell AP, et al. Among authors: lund jl. Oncologist. 2019 May;24(5):632-639. doi: 10.1634/theoncologist.2018-0423. Epub 2019 Feb 6. Oncologist. 2019. PMID: 30728276 Free PMC article.

6

Noncancer mortality among adolescents and young adults with cancer.

Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB. Anderson C, et al. Among authors: lund jl. Cancer. 2019 Jun 15;125(12):2107-2114. doi: 10.1002/cncr.32063. Epub 2019 Mar 20. Cancer. 2019. PMID: 30892701 Free PMC article.

7

Disparities in Mortality from Noncancer Causes among Adolescents and Young Adults with Cancer.

Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB. Anderson C, et al. Among authors: lund jl. Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1417-1426. doi: 10.1158/1055-9965.EPI-18-1384. Epub 2019 Jun 17. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31209147 Free PMC article.

8

Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice.

Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL. Mitchell AP, et al. Among authors: lund jl. Oncologist. 2020 Jan;25(1):46-54. doi: 10.1634/theoncologist.2019-0338. Epub 2019 Oct 14. Oncologist. 2020. PMID: 31611329 Free PMC article.

9

Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments.

Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Winn AN, Sanoff HK, Lund JL. Mitchell AP, et al. Among authors: lund jl. Oncologist. 2024 Jun 3;29(6):527-533. doi: 10.1093/oncolo/oyae035. Oncologist. 2024. PMID: 38484395 Free PMC article.

10

Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.

Lund JL, Sturmer T, Sanoff HK. Lund JL, et al. J Geriatr Oncol. 2016 May;7(3):176-86. doi: 10.1016/j.jgo.2016.01.011. Epub 2016 Feb 23. J Geriatr Oncol. 2016. PMID: 26926829 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page